Brett KM, Madans JH: Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997, 145: 536-545.
Article
CAS
PubMed
Google Scholar
Hemminki E, Topo P: Prescribing of hormone therapy in menopause and postmenopause. J Psychosom Obstet Gynecol. 1997, 18: 145-157.
Article
CAS
Google Scholar
Mattox JH, Shulman LP: Combined oral hormone replacement therapy formulations. Am J Obstet Gynecol. 2001, 185 (suppl): S38-S46. 10.1067/mob.2001.117417.
Article
CAS
PubMed
Google Scholar
Pukkala E, Tulenheimo-Silfvast A, Leminen A: Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994–1997. Cancer Causes Control. 2001, 12: 111-115. 10.1023/A:1008934919159.
Article
CAS
PubMed
Google Scholar
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000, 283: 485-491. 10.1001/jama.283.4.485.
Article
CAS
PubMed
Google Scholar
Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000, 92: 328-332. 10.1093/jnci/92.4.328.
Article
CAS
PubMed
Google Scholar
Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C: Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999, 10: 253-260. 10.1023/A:1008909128110.
Article
CAS
PubMed
Google Scholar
Magnusson C, Baron JA, Correia N, Bergström R, Adami H-O, Persson I: Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer. 1999, 81: 339-344. 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y.
Article
CAS
PubMed
Google Scholar
Söderqvist G: Effects of sex steroids on proliferation in normal mammary tissue. Ann Med. 1998, 30: 511-524.
Article
PubMed
Google Scholar
Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993, 15: 17-35.
CAS
PubMed
Google Scholar
Foidart J-M, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, de Lignières B: Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998, 69: 963-969. 10.1016/S0015-0282(98)00042-9.
Article
CAS
PubMed
Google Scholar
Hargreaves DF, Knox F, Swindell R, Potten CS, Bundred NJ: Epithelial proliferation and hormone receptor status in the normal postmenopausal breast and the effects of hormone replacement therapy. Br J Cancer. 1998, 78: 945-949.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999, 84: 4559-4565. 10.1210/jc.84.12.4559.
CAS
PubMed
Google Scholar
Raafat AM, Hofseth LJ, Haslam SZ: Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model. Am J Obstet Gynecol. 2001, 184: 340-349. 10.1067/mob.2001.110447.
Article
CAS
PubMed
Google Scholar
Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995, 332: 1589-1593. 10.1056/NEJM199506153322401.
Article
CAS
PubMed
Google Scholar
Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Bogdan G, Willett WC: Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995, 142: 788-795.
CAS
PubMed
Google Scholar
Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997, 350: 1047-1059. 10.1016/S0140-6736(97)08233-0.
Article
Google Scholar
Chen C-L, Weiss NS, Newcomb P, Barlow W, White E: Hormone replacement therapy in relation to breast cancer. JAMA. 2002, 287: 734-741. 10.1001/jama.287.6.734.
Article
CAS
PubMed
Google Scholar
Colditz GA, Rosner B: Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000, 152: 950-964. 10.1093/aje/152.10.950.
Article
CAS
PubMed
Google Scholar
Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ: Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002, 11: 593-600.
CAS
PubMed
Google Scholar
Kirsh V, Kreiger N: Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002, 13: 583-590. 10.1023/A:1016330024268.
Article
PubMed
Google Scholar
Li CI, Weiss NS, Stanford JL, Daling JR: Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000, 88: 2570-2577. 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O.
Article
CAS
PubMed
Google Scholar
Ursin G, Tseng C-C, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK: Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?. J Clin Oncol. 2002, 20: 699-706. 10.1200/JCO.20.3.699.
Article
CAS
PubMed
Google Scholar
Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.
Article
Google Scholar
Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002, 288: 58-66. 10.1001/jama.288.1.58.
Article
CAS
PubMed
Google Scholar
Nanda K, Bastian LA, Schulz K: Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol. 2002, 186: 325-334. 10.1067/mob.2002.121077.
Article
CAS
PubMed
Google Scholar
Boyd NF, Martin LJ, Stone J, Greenberg C, Minkin S, Yaffe MJ: Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention. Curr Oncol Rep. 2001, 3: 314-321.
Article
CAS
PubMed
Google Scholar
Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E: Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med. 1999, 130: 262-269.
Article
CAS
PubMed
Google Scholar
Persson I, Thurfjell E, Holmberg L: Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol. 1997, 15: 3201-3207.
CAS
PubMed
Google Scholar
Sendag F, Terek MC, Ozsener S, Oztekin K, Bilgin O, Bilgen I, Memis A: Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril. 2001, 76: 445-450. 10.1016/S0015-0282(01)01935-5.
Article
CAS
PubMed
Google Scholar
Erel CT, Esen G, Seyisoglu H, Elter K, Uras C, Ertungealp E, Aksu MF: Mammographic density increase in women receiving different hormone replacement regimens. Maturitas. 2001, 40: 151-157. 10.1016/S0378-5122(01)00236-5.
Article
CAS
PubMed
Google Scholar
Lundström E, Wilczek B, von Palffy Z, Söderqvist G, von Schoultz B: Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol. 1999, 181: 348-352.
Article
PubMed
Google Scholar
Wren BG: Megatrials of hormonal replacement therapy. Drugs Aging. 1998, 12: 343-348.
Article
CAS
PubMed
Google Scholar